Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) EBT Margin (2018 - 2026)

Exagen filings provide 9 years of EBT Margin readings, the most recent being 22.71% for Q1 2026.

  • On a quarterly basis, EBT Margin rose 149.0% to 22.71% in Q1 2026 year-over-year; TTM through Mar 2026 was 29.36%, a 205.0% decrease, with the full-year FY2025 number at 29.89%, down 275.0% from a year prior.
  • EBT Margin hit 22.71% in Q1 2026 for Exagen, up from 28.02% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 19.69% in Q2 2024 to a low of 192.87% in Q2 2022.
  • Median EBT Margin over the past 5 years was 40.2% (2024), compared with a mean of 53.15%.
  • Biggest five-year swings in EBT Margin: tumbled -14269bps in 2022 and later surged 15741bps in 2023.
  • Exagen's EBT Margin stood at 117.76% in 2022, then surged by 66bps to 40.25% in 2023, then skyrocketed by 32bps to 27.46% in 2024, then dropped by -2bps to 28.02% in 2025, then increased by 19bps to 22.71% in 2026.
  • The last three reported values for EBT Margin were 22.71% (Q1 2026), 28.02% (Q4 2025), and 41.09% (Q3 2025) per Business Quant data.